Importantly, we show that five specific myeloid cell subtype gene signatures (MC2–MC5, and MC7) are independent prognostic indicators of glioma patient survival, independent of known covariates of glioma patient survival, such as IDH mutation and MGMT methylation status. This evidence concerns the gene IDH1 and central nervous system cancer.